Procter & Gamble Health Limited (PGHL.BO)
INR 5459.2
(-0.25%)
INR 5459.2
(-0.25%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.78 Billion INR | -33.38% |
| 2022 | 8.67 Billion INR | 12.03% |
| 2021 | 7.74 Billion INR | 18.4% |
| 2020 | 6.54 Billion INR | 62.84% |
| 2019 | 4.01 Billion INR | -24.64% |
| 2018 | 5.33 Billion INR | 19.15% |
| 2017 | 4.47 Billion INR | -20.45% |
| 2016 | 5.62 Billion INR | 15.9% |
| 2015 | 4.85 Billion INR | 8.71% |
| 2014 | 4.46 Billion INR | 7.98% |
| 2013 | 4.13 Billion INR | 11.4% |
| 2012 | 3.71 Billion INR | 25.22% |
| 2011 | 2.96 Billion INR | -1.61% |
| 2010 | 3.01 Billion INR | 12.8% |
| 2009 | 2.67 Billion INR | 16.36% |
| 2008 | 2.29 Billion INR | 21.84% |
| 2007 | 1.88 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.73 Billion INR | 16.42% |
| 2023 FY | 5.78 Billion INR | -33.38% |
| 2023 Q4 | 1.48 Billion INR | 18.27% |
| 2023 Q3 | 1.25 Billion INR | -42.66% |
| 2023 Q2 | 2.19 Billion INR | 0.82% |
| 2023 Q1 | 2.17 Billion INR | 5.06% |
| 2022 Q4 | 2.07 Billion INR | -6.14% |
| 2022 FY | 8.67 Billion INR | 12.03% |
| 2022 Q3 | 2.2 Billion INR | -3.36% |
| 2022 Q2 | 2.28 Billion INR | 8.29% |
| 2022 Q1 | 2.11 Billion INR | 31.83% |
| 2021 Q1 | 1.92 Billion INR | 25.67% |
| 2021 Q3 | 1.87 Billion INR | 0.37% |
| 2021 Q4 | 1.6 Billion INR | -14.64% |
| 2021 Q2 | 1.86 Billion INR | -3.13% |
| 2021 FY | 7.74 Billion INR | 18.4% |
| 2020 Q3 | 1.52 Billion INR | -13.74% |
| 2020 Q2 | 1.76 Billion INR | 4.51% |
| 2020 FY | 6.54 Billion INR | 62.84% |
| 2020 Q1 | 1.69 Billion INR | 12.85% |
| 2020 Q4 | 1.53 Billion INR | 0.74% |
| 2019 FY | 4.01 Billion INR | -24.64% |
| 2019 Q3 | 1.47 Billion INR | 0.0% |
| 2019 Q1 | 1.47 Billion INR | -14.44% |
| 2019 Q4 | 1.49 Billion INR | 1.25% |
| 2018 Q2 | 1.37 Billion INR | -11.44% |
| 2018 FY | 5.33 Billion INR | 19.15% |
| 2018 Q4 | 1.72 Billion INR | 14.02% |
| 2018 Q3 | 1.5 Billion INR | 9.43% |
| 2018 Q1 | 1.55 Billion INR | 2.89% |
| 2017 FY | 4.47 Billion INR | -20.45% |
| 2017 Q4 | 1.51 Billion INR | 12.36% |
| 2017 Q3 | 1.34 Billion INR | 4.66% |
| 2017 Q2 | 1.28 Billion INR | 0.63% |
| 2017 Q1 | 1.27 Billion INR | 20.49% |
| 2016 Q1 | 1.57 Billion INR | 9.66% |
| 2016 FY | 5.62 Billion INR | 15.9% |
| 2016 Q4 | 1.06 Billion INR | -23.46% |
| 2016 Q3 | 1.38 Billion INR | -10.79% |
| 2016 Q2 | 1.55 Billion INR | -1.45% |
| 2015 Q4 | 1.43 Billion INR | 15.02% |
| 2015 Q1 | 1.25 Billion INR | 4.35% |
| 2015 Q2 | 1.23 Billion INR | -1.95% |
| 2015 Q3 | 1.25 Billion INR | 1.51% |
| 2015 FY | 4.85 Billion INR | 8.71% |
| 2014 Q1 | 1.17 Billion INR | 2.5% |
| 2014 Q4 | 1.2 Billion INR | 15.99% |
| 2014 Q3 | 1.03 Billion INR | -8.04% |
| 2014 FY | 4.46 Billion INR | 7.98% |
| 2014 Q2 | 1.12 Billion INR | -4.05% |
| 2013 Q2 | 984.48 Million INR | -8.27% |
| 2013 Q3 | 1.01 Billion INR | 2.69% |
| 2013 Q4 | 1.14 Billion INR | 13.54% |
| 2013 FY | 4.13 Billion INR | 11.4% |
| 2013 Q1 | 1.07 Billion INR | -2.96% |
| 2012 Q1 | 987.39 Million INR | 2.66% |
| 2012 Q4 | 1.1 Billion INR | 13.97% |
| 2012 Q3 | 970.41 Million INR | 36.57% |
| 2012 FY | 3.71 Billion INR | 25.22% |
| 2012 Q2 | 710.56 Million INR | -28.04% |
| 2011 Q3 | 759.03 Million INR | 15.59% |
| 2011 Q1 | 906.52 Million INR | 0.0% |
| 2011 FY | 2.96 Billion INR | -1.61% |
| 2011 Q4 | 961.8 Million INR | 26.71% |
| 2011 Q2 | 656.63 Million INR | -27.57% |
| 2010 FY | 3.01 Billion INR | 12.8% |
| 2009 FY | 2.67 Billion INR | 16.36% |
| 2008 FY | 2.29 Billion INR | 21.84% |
| 2007 FY | 1.88 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 72.553% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -271.428% |
| Sigachi Industries Limited | 2 Billion INR | -188.74% |
| Bal Pharma Limited | 770.19 Million INR | -650.641% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 6.667% |
| Medico Remedies Limited | 262.14 Million INR | -2105.429% |
| Lasa Supergenerics Limited | 121.02 Million INR | -4676.832% |
| Venus Remedies Limited | 2.18 Billion INR | -164.888% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1059.718% |
| Alpa Laboratories Limited | 188.89 Million INR | -2960.642% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -94.525% |
| Shilpa Medicare Limited | 3.54 Billion INR | -63.0% |
| Aarti Drugs Limited | 8.31 Billion INR | 30.48% |
| Lupin Limited | 123.71 Billion INR | 95.327% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 96.262% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 95.383% |
| Windlas Biotech Limited | 1.33 Billion INR | -331.834% |
| Suven Life Sciences Limited | -200.79 Million INR | 2979.226% |
| Eris Lifesciences Limited | 10.42 Billion INR | 44.552% |
| Valiant Laboratories Limited | -60.66 Million INR | 9630.199% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 74.531% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -571.319% |
| Ipca Laboratories Limited | 29.8 Billion INR | 80.606% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -56.447% |
| Achyut Healthcare Limited | 4.86 Million INR | -118834.376% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 97.763% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -292.81% |
| RPG Life Sciences Limited | 2.48 Billion INR | -132.839% |
| Mankind Pharma Limited | 44.52 Billion INR | 87.014% |
| Laurus Labs Limited | 24.62 Billion INR | 76.518% |
| Piramal Pharma Limited | 24.47 Billion INR | 76.374% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -513.477% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 87.635% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 78.412% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 91.662% |
| Unichem Laboratories Limited | 4.86 Billion INR | -18.838% |
| Sequent Scientific Limited | 2.97 Billion INR | -94.089% |
| Novartis India Limited | 1.32 Billion INR | -335.707% |
| Wanbury Limited | 1.73 Billion INR | -234.061% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -40.214% |
| Wockhardt Limited | 16.24 Billion INR | 64.4% |
| Themis Medicare Limited | 1.5 Billion INR | -284.426% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -785.916% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 70.568% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 53.5% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 96.466% |
| Divi's Laboratories Limited | 32.44 Billion INR | 82.178% |
| NATCO Pharma Limited | 25.73 Billion INR | 77.536% |
| Gufic Biosciences Limited | 4.16 Billion INR | -38.719% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -26.209% |
| Ind-Swift Limited | 2.17 Billion INR | -166.114% |
| FDC Limited | 8.33 Billion INR | 30.635% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -2899.787% |
| Granules India Limited | 16.79 Billion INR | 65.585% |
| Medicamen Biotech Limited | 495.49 Million INR | -1066.793% |
| Alkem Laboratories Limited | 52.29 Billion INR | 88.945% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 7.092% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -39553.765% |
| Brooks Laboratories Limited | 65.62 Million INR | -8710.424% |
| Megasoft Limited | 342.07 Million INR | -1590.117% |
| ZIM Laboratories Limited | 1.26 Billion INR | -356.347% |
| Strides Pharma Science Limited | 14.38 Billion INR | 59.818% |
| Neuland Laboratories Limited | 8.24 Billion INR | 29.904% |
| Morepen Laboratories Limited | 6.16 Billion INR | 6.166% |
| Hikal Limited | 3.14 Billion INR | -83.941% |
| Indoco Remedies Limited | 6.04 Billion INR | 4.302% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 0.857% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -831.767% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -721.683% |
| Hester Biosciences Limited | 1.27 Billion INR | -353.924% |